Hematopoietic progenitor cell mobilization and harvesting in children with malignancies: Do the advantages of pegfilgrastim really translate into clinical benefit?

Bone Marrow Transplantation

Volumn 43, Issue 12, 2009, Pages 919-925

  Merlin, E ^a,b,c   Zohar, S ^d   Jerome C ^e   Veyrat Masson, R ^a,c   Marceau, G ^a,c   Paillard, C ^a,b,c   Auvrignon, A ^f   Le Moine, P ^g   Gandemer, V ^h   Sapin, V ^a,c   Halle, P ^a,b,c   Boiret Dupre N ^a,c   Chevret, S ^d   Demeocq F ^a,b,c   Dubray, C ^a,b,c   Kanold, J ^a,b,c  

^a HÔTEL DIEU   (France)

^b INSERM   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e Institut de Cancerologie de la Loire   (France)

^f ARMAND TROUSSEAU HOSPITAL   (France)

^g Hôpital des Enfants   (France)

^h RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ANOREXIA; APHERESIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE PAIN; CD4+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HEMATOPOIETIC STEM CELL; HUMAN; HYPERURICEMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LEUKOCYTOSIS; LYMPHOCYTE COUNT; MYALGIA; MYELOABLATIVE CONDITIONING; NAUSEA; NEUTROPHIL COUNT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; SPLENOMEGALY; STEM CELL MOBILIZATION; TREATMENT OUTCOME;

ADOLESCENT; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FILGRASTIM; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; KINETICS; NEOPLASMS; TREATMENT OUTCOME;

EID: 67649870306     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.412     Document Type: Article

References (26)

1. Merlin E, Piguet C, Auvrignon A, Rubie H, Demeocq F, Kanold J. The pros and cons of split-dose granulocyte colony-stimulating factor alone rather than a single high dose for hematopoieticprogenitor cell mobilization in small children (<15 kg) with solid tumors. Haematologica 2006; 91: 1004-1005.
2. Perez-Duenas B, Alcorta I, Estella J, Rives S, Toll T, Tuset E. Safety and efficacy of high-dose G-CSF (24 microg/kg) alone for PBSC mobilization in children. Bone Marrow Transplant 2002; 30: 987-988.
3. Kanold J, Berger M, Halle P, Rapatel C, Shoebfer C, de Lumley L et al Kinetics of hematopoietic progenitor cell release induced by G-CSF-alone in children with solid tumors and leukemias. Bone Marrow Transplant 1998; 21: 59-63.
4. Sevilla J, Gonzalez-Vicent M, Madero L, Garcia-Sanchez F, Diaz MA. Granulocyte colony-stimulating factor alone at 12 microg/kg twice a day for 4 days for peripheral blood progenitor cell priming in pediatric patients. Bone Marrow Transplant 2002; 30: 417-420.
5. Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, KerzicP et al. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999; 27: 1724-1734.
6. Isidori A, Tani M, Bonifazi F, Zinzani P, Curti A, Motta MR et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 2005; 90: 225-231.
7. Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2005; 35: 33-36.
8. te Poele EM, Kamps WA, Tamminga RY, Leeuw JA, Postma A, de Bont ES. Pegfilgrastim in pediatricc ancer patients. J Pediatr Hematol Oncol 2005; 27: 627-629.
9. Wendelin G, Lackner H, Schwinger W, Sovinz P, Urban C. Once-per-cycle pegfilgrastim versus daily filgrastim in pediatric patients with Ewing sarcoma. J Pediatr Hematol Oncol 2005; 27: 449-451.
10. André N, Kababri ME, Bertrand P, Rome A, Coze C, Gentet JC et al Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy. Anticancer Drugs 2007; 18: 277-281.
11. Dallorso S, Berger M, Caviglia I, Emanueli T, Faraci M, Scarso L et al. Prospective single-arm study of pegfilgrastim activity and safety in children with poor-risk malignant tumours receiving chemotherapy. Bone Marrow Transplant 2008; 42: 507-513.
12. Russel N, Mesters R, Schubert J, Boogaerts M, Johnsen H, del Canizo C. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Haematologica 2008; 93: 405-412.
13. Kanold J, Halle P, Berger M, Rapatel C, Palcoux JB, Rouzier C et al Large-volume leukapheresis procedure for peripheral blood progenitor cell collection in children weighing 15 kg or less: Efficacy and safety evaluation. Med Pediatr Oncol 1999; 32: 7-10.
14. Biganzoli L, Untch M, Skacel T, Pico JL. Neulasta (pegfilgrastim): A once-per-cycle option for the management of chemotherapy-induced neutropenia. Semin Oncol 2004; 31: 27-34.
15. Roskos LK, Lum P, Lockbaum P, Schwab G, Yang BB. Pharmacokinetic/ pharmacodynamic modeling of pegfilgrastim in healthy subjects. J Clin Pharmacol 2006; 46: 747-757.
16. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213-226.
17. Kanold J, Halle P, Tchirkov A, Berger M, Giarratana MC, Kobari L et al. Ex vivo expansion of autologous PB CD34+ cells provides a purging effect in children with neuroblastoma. Bone Marrow Transplant 2003; 32: 485-488.
18. Berry DA. Monitoring accumulating data in a clinical trial. Biometrics 1989; 45: 1197-1211.
19. Zohar S, Teramukai S, Zhou Y. Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: A tutorial. Contemp Clin Trials 2008; 29: 608-616.
20. Zohar S, Chevret S. The continual reassessment method: Comparison of Bayesian stopping rules for dose-ranging studies. Stat Med 2001; 20: 2827-2843.
21. Hill G, Morris E, Fuery M, Hutchins C, Butler J, Grigg A. Allogeneicstem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF. Biol Blood Marrow Transplant 2006; 12: 603-607.
22. Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003; 21: 514-519.
23. Halle P, Kanold J, Rapatel C, Boiret N, Berger M, Stephan JL et al Granulocyte colony-stimulating factor alone at 20 micrograms/kg vs 10 micrograms/kg for peripheral blood stem cell mobilization in children. Pediatr Transplant 2000; 4: 285-288.
24. Watring NJ, Wagner TW, Stark JJ. Spontaneous splenic rupture secondary to pegfilgrastim to prevent neutropenia in a patient with non-small-cell lung carcinoma. Am J Emerg Med 2007; 25: 247-248.
25. Nuamah NM, Goker H, Kilic YA, Dagmoura H, Cakmak A. Spontaneous splenicrupture in a healthy allogeneicdonor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (G-CSF). A case report and review of the literature. Haematologica 2006; 91: ECR08.
26. Relling MV, Boyett JM, Blanco JG, Raimondi S, Behm FG, Sandlund JT et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 2003; 101 3862-3867.